Seeking Alpha
Long/short equity, contrarian
Profile| Send Message|
( followers)  

By David Powers

Below is a list of heavily traded (over 1M shares traded, on average, daily) biotechs with the highest price-to-book ratios and price-to-sales ratios over 10. They all have notably high P/E ratios as well.

1. Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Price to book: 65.04 - Price to sales: 11.54

Jazz Pharmaceuticals plc describes itself as a dynamic specialty biopharmaceutical company that identifies, develops and commercializes innovative products to address unmet medical needs in focused therapeutic areas, always keeping in mind its mission to improve patients' lives.

Chart
(Click to enlarge)

Its stock currently trades around $51.15 with 42.16M shares out, giving it a market cap of $2.11B. Institutional ownership stands at about 92% and the current P/E ratio is 20.27. The average analyst 12-month price target for JAZZ is $53.57.

Products:

JAZZ
(Click to enlarge)

2. Questcor Pharmaceuticals, Inc. (NASDAQ:QCOR)

Price to book: 19.02 - Price to sales: 13.35

Questcor describes itself as a biopharmaceutical company whose products help patients with serious, difficult-to-treat medical conditions. Its efforts are currently focused on the fields of neurology and nephrology, areas of medicine which have significant unmet medical needs.

Chart
(Click to enlarge)

Its stock currently trades around $36 with 62.73M shares out, giving it a market cap of $2.26B. Institutional ownership stands at about 95% and the current P/E ratio is 43.27. The average analyst 12-month price target for QCOR is $51.86.

Products:

QCOR
(Click to enlarge)

3. Akorn, Inc. (NASDAQ:AKRX)

Price to book: 13.84 - Price to sales: 10.24

Akorn describes itself as a niche generic pharmaceutical company engaged in the development, manufacture and marketing of multi-source and branded pharmaceutical products in the areas of ophthalmology, antidotes, anti-infectives, and controlled substances for pain management and anesthesia in the U.S. and across the globe.

Chart
(Click to enlarge)

Its stock currently trades around $12.46 with 94.84M shares out, giving it a market cap of $1.18B. Institutional ownership stands at about 65% and the current P/E ratio is 21.07. The average analyst 12-month price target for AKRX is $13.25.

Products:

AKRX
(Click to enlarge)

4. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN)

Price to book: 13.77 - Price to sales: 19.93

Alexion is described as is a biopharmaceutical company engaged in the discovery, development and commercialization of therapeutic products aimed at treating patients with severe and life-threatening disease states, including those in the therapeutic areas of hematology, nephrology (including transplant rejection), neurology, ophthalmology and cancer.

Chart
(Click to enlarge)

Its stock currently trades around $84.29 with 185.15M shares out, giving it a market cap of $15.61B. Institutional ownership stands at about 96% and the current P/E ratio is 93.06. The average analyst 12-month price target for ALXN is $88.

Pipeline:

ALXN
(Click to enlarge)

Source: 4 Heavily Traded Biotechs With The Highest P/B Ratios And PSRs Over 10